Benefits of CFTR Modification Beyond FEV1 Improvement

Volume 5, Issue 12.

In this issue of eCysticfibrosis Review Dr. Chris Goss of the University of Washington Medical Center. Dr. Goss discusses the benefits of CFTR modification beyond Fev1 improvement through the use of patient-cases.

Personalizing DMT Regimens/The Risks of Medication Non-Adherence

Volume 1, Issue 2.

Arun Venkatesan, MD, PhD and Scott Douglas Newsome, DO cover the important topics of personalizing DMT regimens and the risk of medication non-adherence in the format of case-study scenarios for the clinical practice.

To read a companion newsletter click here.